Michael T. Dellinger
YOU?
Author Swipe
View article: Normal cardiac lymphatics and their mimics
Normal cardiac lymphatics and their mimics Open
This is the first study detailing normal lymphatic vessel distribution at various cardiac anatomical sites using a lymphatic reporter mouse model, multiple markers, and modern imaging modalities, providing a blueprint for future studies. W…
View article: Lymphatic Malformations with Activating KRAS Mutations Impair Lymphatic Valve Development Through Matrix Metalloproteinases
Lymphatic Malformations with Activating KRAS Mutations Impair Lymphatic Valve Development Through Matrix Metalloproteinases Open
BACKGROUND Lymphatic malformations (LMs) are lesions due to inherited or somatic mutations that lead to a defective lymphatic vasculature. Activating KRAS mutations have been identified recently in LM patients with lymphedema, chylous asci…
View article: A single-cell atlas of normal and KRASG12D-malformed lymphatic vessels
A single-cell atlas of normal and KRASG12D-malformed lymphatic vessels Open
Somatic activating mutations in KRAS can cause complex lymphatic anomalies (CLAs). However, the specific processes that drive KRAS-mediated CLAs have yet to be fully elucidated. Here, we used single-cell RNA sequencing to construct an atla…
View article: Vegfc-expressing cells form heterotopic bone after musculoskeletal injury
Vegfc-expressing cells form heterotopic bone after musculoskeletal injury Open
Heterotopic ossification (HO) is a challenging condition that occurs after musculoskeletal injury and is characterized by the formation of bone in non-skeletal tissues. While the effect of HO on blood vessels is well established, little is…
View article: Meeting Report for the 2023 International Scientific Conference on Complex Lymphatic Anomalies
Meeting Report for the 2023 International Scientific Conference on Complex Lymphatic Anomalies Open
Objectives: Complex lymphatic anomalies (CLAs) are rare diseases with variable clinical manifestations caused by the abnormal development of lymphatic vessels. The Lymphatic Malformation Institute (LMI), Lymphangiomatosis & Gorham’s Diseas…
View article: Trametinib Inhibits Lymphatic Vessel Invasion of Bone in a Mouse Model of Gorham-Stout Disease
Trametinib Inhibits Lymphatic Vessel Invasion of Bone in a Mouse Model of Gorham-Stout Disease Open
Objective: Gorham-Stout disease (GSD) is a rare lymphatic anomaly that can be caused by somatic activating mutations in KRAS . This discovery has led investigators to suggest that MEK inhibitors could be a novel treatment for GSD. However,…
View article: Hyperactive KRAS/MAPK signaling disrupts normal lymphatic vessel architecture and function
Hyperactive KRAS/MAPK signaling disrupts normal lymphatic vessel architecture and function Open
Complex lymphatic anomalies (CLAs) are sporadically occurring diseases caused by the maldevelopment of lymphatic vessels. We and others recently reported that somatic activating mutations in KRAS can cause CLAs. However, the mechanisms by …
View article: Supplementary Methods from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas
Supplementary Methods from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas Open
Supplementary Methods PDF file - 123K, This file contains the Supplementary materials and methods linked to the manuscript. In addition the references associated with the materials are reported
View article: Supplementary Figure 1 from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas
Supplementary Figure 1 from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas Open
Supplementary Figure 1 PDF file - 311K, This Figure shows that the KrasG12D;Ink4a/Arf -/- mice show increased tumor burden, increased Ki-67, Cyclin D1 expression and decreased survival compared to KrasG12D;Ink4a/Arf +/+ mice
View article: Supplementary Figure 6 from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas
Supplementary Figure 6 from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas Open
Supplementary Figure 6 PDF file - 141K, This Figure shows that FAK is co-expressed with RHOA in lung adenocarcinomas. In addition, we provide the validation of RHOA-GTP antibody on human specimens by IHC
View article: Supplemental Data, Figures, and Table from Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer
Supplemental Data, Figures, and Table from Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer Open
Supplementary Figure 1. (a) Representative images of metastasis to the liver of control mice in Colo357 model was shown by H&E staining. Total magnifications are 100X and 200X. Scale bar, 50μm. (b) Colo357 human pancreatic cancer cells (1…
View article: Supplementary Figure 3 from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas
Supplementary Figure 3 from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas Open
Supplementary Figure 3 PDF file - 76K, This Figure shows the knockdown efficiency of shRNAs against KRAS and that MEK1/2 inhibition suppresses RHOA
View article: Supplementary Figure 3 from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas
Supplementary Figure 3 from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas Open
Supplementary Figure 3 PDF file - 76K, This Figure shows the knockdown efficiency of shRNAs against KRAS and that MEK1/2 inhibition suppresses RHOA
View article: Supplementary Figure 5 from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas
Supplementary Figure 5 from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas Open
Supplementary Figure 5 PDF file - 199K, This Figure shows that FAK is a critical target of RHOA in mutant KRAS;INK4a/ARF deficient NSCLC cells
View article: Data from Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer
Data from Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer Open
Resistance to standard therapy remains a major challenge in the treatment of pancreatic ductal adenocarcinoma (PDA). Although anti-VEGF therapy delays PDA progression, therapy-induced hypoxia results in a less differentiated mesenchymal-li…
View article: Supplementary Figure 7 from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas
Supplementary Figure 7 from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas Open
Supplementary Figure 7 PDF file - 205K, This Figure shows that pharmacological inhibition of FAK results in suppression of NSCLC in vivo
View article: Supplementary Figure 1 from Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts
Supplementary Figure 1 from Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts Open
PDF file, 156K, NSCLC cell line expression of PDGFRα.
View article: Supplementary Figure 2 from Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts
Supplementary Figure 2 from Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts Open
PDF file, 156K, Species and target specificity of IMC-3G3 and 1E10.
View article: Supplementary Figure 7 from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas
Supplementary Figure 7 from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas Open
Supplementary Figure 7 PDF file - 205K, This Figure shows that pharmacological inhibition of FAK results in suppression of NSCLC in vivo
View article: Data from Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts
Data from Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts Open
In lung cancer, platelet-derived growth factor receptor α (PDGFRα) is expressed frequently by tumor-associated stromal cells and by cancer cells in a subset of tumors. We sought to determine the effect of targeting stromal PDGFRα in precli…
View article: Supplementary Figure 4 from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas
Supplementary Figure 4 from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas Open
Supplementary Figure 4 PDF file - 169K, This Figure shows that RHOA activation is essential for the survival of NSCLC expressing mutant KRAS in association with INK4a/ARF or p53 deficiency
View article: Supplementary Figure 2 from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas
Supplementary Figure 2 from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas Open
Supplementary Figure 2 PDF file - 182K, This Figure shows the activation status of RhoA and Rac1 in mouse lungs and validation of RhoA-GTP antibody on mouse lung tissue by IHC
View article: Supplementary Figure 4 from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas
Supplementary Figure 4 from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas Open
Supplementary Figure 4 PDF file - 169K, This Figure shows that RHOA activation is essential for the survival of NSCLC expressing mutant KRAS in association with INK4a/ARF or p53 deficiency
View article: Supplementary Figure Legend from Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts
Supplementary Figure Legend from Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts Open
PDF file, 46K.
View article: Supplementary Figure 5 from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas
Supplementary Figure 5 from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas Open
Supplementary Figure 5 PDF file - 199K, This Figure shows that FAK is a critical target of RHOA in mutant KRAS;INK4a/ARF deficient NSCLC cells
View article: Supplementary Figure Legend from Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts
Supplementary Figure Legend from Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts Open
PDF file, 46K.
View article: Supplementary Figure 2 from Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts
Supplementary Figure 2 from Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts Open
PDF file, 156K, Species and target specificity of IMC-3G3 and 1E10.
View article: Data from Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts
Data from Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts Open
In lung cancer, platelet-derived growth factor receptor α (PDGFRα) is expressed frequently by tumor-associated stromal cells and by cancer cells in a subset of tumors. We sought to determine the effect of targeting stromal PDGFRα in precli…
View article: Supplementary Figure 1 from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas
Supplementary Figure 1 from RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas Open
Supplementary Figure 1 PDF file - 311K, This Figure shows that the KrasG12D;Ink4a/Arf -/- mice show increased tumor burden, increased Ki-67, Cyclin D1 expression and decreased survival compared to KrasG12D;Ink4a/Arf +/+ mice